Top

Published in:

01-01-2021 | Glioblastoma | Topic Review

Immune suppression in gliomas

Authors: Matthew M. Grabowski, Eric W. Sankey, Katherine J. Ryan, Pakawat Chongsathidkiet, Selena J. Lorrey, Daniel S. Wilkinson, Peter E. Fecci

Published in: Journal of Neuro-Oncology | Issue 1/2021

Abstract

Introduction

The overall survival in patients with gliomas has not significantly increased in the modern era, despite advances such as immunotherapy. This is in part due to their notorious ability to suppress local and systemic immune responses, severely restricting treatment efficacy.

Methods

We have reviewed the preclinical and clinical evidence for immunosuppression seen throughout the disease process in gliomas. This review aims to discuss the various ways that brain tumors, and gliomas in particular, co-opt the body’s immune system to evade detection and ensure tumor survival and proliferation.

Results

A multitude of mechanisms are discussed by which neoplastic cells evade detection and destruction by the immune system. These include tumor-induced T-cell and NK cell dysfunction, regulatory T-cell and myeloid-derived suppressor cell expansion, M2 phenotypic transformation in glioma-associated macrophages/microglia, upregulation of immunosuppressive glioma cell surface factors and cytokines, tumor microenvironment hypoxia, and iatrogenic sequelae of immunosuppressive treatments.

Conclusions

Gliomas create a profoundly immunosuppressive environment, both locally within the tumor and systemically. Future research should aim to address these immunosuppressive mechanisms in the effort to generate treatment options with meaningful survival benefits for this patient population.

Wrensch M, Minn Y, Chew T et al (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278–299. https://doi.org/10.1093/neuonc/4.4.278CrossRefPubMedPubMedCentral

Dunn GP, Fecci PE, Curry WT (2012) Cancer immunoediting in malignant glioma. Neurosurgery 71:201–22; discussion 222–3. https://doi.org/10.1227/NEU.0b013e31824f840d

Woroniecka KI, Rhodin KE, Chongsathidkiet P et al (2018) T-Cell dysfunction in glioblastoma: applying a new framework. Clin Cancer Res 24:3792–3802CrossRef

Akbar AN, Henson SM, Lanna A (2016) Senescence of T lymphocytes: implications for enhancing human immunity. Trends Immunol 37:866–876CrossRef

Focosi D, Bestagno M, Burrone O, Petrini M (2010) CD57 + T lymphocytes and functional immune deficiency. J Leukoc Biol 87:107–116. https://doi.org/10.1189/jlb.0809566CrossRefPubMed

Strioga M, Pasukoniene V, Characiejus D (2011) CD8+CD28- and CD8+CD57+ T cells and their role in health and disease. Immunology 134:17–32CrossRef

Fornara O, Odeberg J, Solberg NW et al (2015) Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery. Oncoimmunology 4:1–14. https://doi.org/10.1080/2162402X.2015.1036211CrossRef

Linton PJ, Dorshkind K (2004) Age-related changes in lymphocyte development and function. Nat Immunol 5:133–139CrossRef

Wheeler CJ, Black KL, Liu G et al (2003) Thymic CD8 + T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 171:4927–4933. https://doi.org/10.4049/jimmunol.171.9.4927CrossRefPubMed

10.

Theofilopoulos AN, Kono DH, Baccala R (2017) The multiple pathways to autoimmunity. Nat Immunol 18:716–724CrossRef

11.

Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7–13CrossRef

12.

Strand S, Hofmann WJ, Hug H et al (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—A mechanism of immune evasion? Nat Med 2:1361–1366. https://doi.org/10.1038/nm1296-1361CrossRefPubMed

13.

Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305–334. https://doi.org/10.1146/annurev.immunol.21.120601.141110CrossRefPubMed

14.

Chiodetti L, Choi S, Barber DL, Schwartz RH (2006) Adaptive tolerance and clonal anergy are distinct biochemical states. J Immunol 176:2279–2291. https://doi.org/10.4049/jimmunol.176.4.2279CrossRefPubMed

15.

Wherry EJ, Blattman JN, Murali-Krishna K et al (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77:4911–4927. https://doi.org/10.1128/jvi.77.8.4911-4927.2003CrossRefPubMedPubMedCentral

16.

Woroniecka K, Chongsathidkiet P, Rhodin K et al (2018) T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res 24:4175–4186. https://doi.org/10.1158/1078-0432.CCR-17-1846CrossRefPubMedPubMedCentral

17.

Buggert M, Tauriainen J, Yamamoto T et al (2014) T-bet and eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. https://doi.org/10.1371/journal.ppat.1004251CrossRefPubMedPubMedCentral

18.

Martinez GJ, Pereira RM, Äijö T et al (2015) The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42:265–278. https://doi.org/10.1016/j.immuni.2015.01.006CrossRefPubMedPubMedCentral

19.

Schietinger A, Greenberg PD (2014) Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 35:51–60CrossRef

20.

Chongsathidkiet P, Jackson C, Koyama S et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. https://doi.org/10.1038/s41591-018-0135-2CrossRefPubMedPubMedCentral

21.

Vignali DAA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523–532CrossRef

22.

Samuels V, Barrett JM, Bockman S et al (1989) Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 134:894–902PubMedPubMedCentral

23.

Wainwright DA, Balyasnikova IV, Chang AL et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18:6110–6121. https://doi.org/10.1158/1078-0432.CCR-12-2130CrossRefPubMedPubMedCentral

24.

Schaefer C, Kim GG, Albers A et al (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913–920. https://doi.org/10.1038/sj.bjc.6602407CrossRefPubMedPubMedCentral

25.

Wolf AM, Wolf D, Steurer M et al (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612PubMed

26.

Fecci PE, Mitchell DA, Whitesides JF et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302. https://doi.org/10.1158/0008-5472.CAN-05-3773CrossRefPubMed

27.

El AA, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme1. Neuro Oncol 8:234–243. https://doi.org/10.1215/15228517-2006-006CrossRef

28.

Fecci PE, Sweeney AE, Grossi PM et al (2006) Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12:4294–4305. https://doi.org/10.1158/1078-0432.CCR-06-0053CrossRefPubMed

29.

Poirier M-D, Haban H, El Andaloussi A (2009) A combination of systemic and intracranial anti-CD25 immunotherapy elicits a long-time survival in murine model of glioma. J Oncol 2009:963037. https://doi.org/10.1155/2009/963037CrossRefPubMed

30.

Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66–70. https://doi.org/10.1038/358066a0CrossRefPubMed

31.

Kriegsman BA, Vangala P, Chen BJ et al (2019) Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC Class I antigen presentation and increased PD-L1 expression. J Immunol 203:1999–2010. https://doi.org/10.4049/jimmunol.1900475CrossRefPubMedPubMedCentral

32.

Stewart CA, Laugier-Anfossi F, Vély F et al (2005) Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 102:13224–13229. https://doi.org/10.1073/pnas.0503594102CrossRefPubMed

33.

Moon WY, Powis SJ (2019) Does natural killer cell deficiency (NKD) increase the risk of cancer? NKD may increase the risk of some virus induced cancer. Front Immunol 10:1703CrossRef

34.

Orange JS (2013) Natural killer cell deficiency. J Allergy Clin Immunol 132:515–525CrossRef

35.

Crane CA, Han SJ, Barry JJ et al (2010) TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 12:7–13. https://doi.org/10.1093/neuonc/nop009CrossRefPubMed

36.

Lin A, Yan WH (2015) Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med 21:782–791CrossRef

37.

Kmiecik J, Poli A, Brons NHC et al (2013) Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 264:71–83. https://doi.org/10.1016/j.jneuroim.2013.08.013CrossRefPubMed

38.

Otvos B, Silver DJ, Mulkearns-Hubert EE et al (2016) Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells 34:2026–2039. https://doi.org/10.1002/stem.2393CrossRefPubMedPubMedCentral

39.

Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125:3356–3364CrossRef

40.

Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16:53–65CrossRef

41.

Raychaudhuri B, Ireland PRJ, Ko J et al (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13:591–599. https://doi.org/10.1093/neuonc/nor042CrossRefPubMedPubMedCentral

42.

Nagaraj S, Gabrilovich DI (2007) Myeloid-derived suppressor cells. In: Shurin MR, Smolkin YS (eds) Immune-mediated diseases. Advances in experimental medicine and biology, vol 601. Springer, New York

43.

Raychaudhuri B, Rayman P, Huang P et al (2015) Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol 122:293–301. https://doi.org/10.1007/s11060-015-1720-6CrossRefPubMed

44.

Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–4506. https://doi.org/10.4049/jimmunol.0802740CrossRefPubMedPubMedCentral

45.

Rodriguez PC, Quiceno DG, Ochoa AC (2007) L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109:1568–1573. https://doi.org/10.1182/blood-2006-06-031856CrossRefPubMedPubMedCentral

46.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. https://doi.org/10.1038/nri2506CrossRefPubMedPubMedCentral

47.

Dubinski D, Wölfer J, Hasselblatt M et al (2016) CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol 18:807–818. https://doi.org/10.1093/neuonc/nov280CrossRefPubMed

48.

Yang L, DeBusk LM, Fukuda K et al (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421. https://doi.org/10.1016/j.ccr.2004.08.031CrossRefPubMed

49.

Kujawski M, Kortylewski M, Lee H et al (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367–3377. https://doi.org/10.1172/JCI35213CrossRefPubMedPubMedCentral

50.

Diaz-Montero CM, Salem ML, Nishimura MI et al (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59. https://doi.org/10.1007/s00262-008-0523-4CrossRefPubMed

51.

Gieryng A, Pszczolkowska D, Walentynowicz KA et al (2017) Immune microenvironment of gliomas. Lab Investig 97:498–518CrossRef

52.

Alban TJ, Alvarado AG, Sorensen MD et al (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI insight. https://doi.org/10.1172/jci.insight.122264CrossRefPubMedPubMedCentral

53.

Chai E, Zhang L, Li C (2019) LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression. Cancer Manag Res 11:7307–7315. https://doi.org/10.2147/CMAR.S210545CrossRefPubMedPubMedCentral

54.

Peereboom DM, Alban TJ, Grabowski MM et al (2019) Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. https://doi.org/10.1172/jci.insight.130748CrossRefPubMedPubMedCentral

55.

Hambardzumyan D, Gutmann DH, Kettenmann H (2015) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19:20–27CrossRef

56.

Ginhoux F, Greter M, Leboeuf M et al (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science(80-) 330:841–845. https://doi.org/10.1126/science.1194637CrossRef

57.

Esiri MM, Morris CS (1991) Immunocytochemical study of macrophages and microglial cells and extracellular matrix components in human CNS disease. 2 Non-neoplastic diseases. J Neurol Sci 101:59–72. https://doi.org/10.1016/0022-510X(91)90018-3CrossRefPubMed

58.

Wierzba-Bobrowicz T, Kuchna I, Matyja E (1994) Reaction of microglial cells in human astrocytomas (preliminary report). Folia Neuropathol 32:251–252PubMed

59.

Nishie A, Ono M, Shono T et al (1999) Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 5:1107–1113PubMed

60.

Geranmayeh F, Scheithauer BW, Spitzer C et al (2007) Microglia in gemistocytic astrocytomas. Neurosurgery 60:159–166. https://doi.org/10.1227/01.NEU.0000249192.30786.67CrossRefPubMed

61.

Mieczkowski J, Kocyk M, Nauman P et al (2015) Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma. Oncotarget 6:33077–33090. https://doi.org/10.18632/oncotarget.5310CrossRefPubMedPubMedCentral

62.

Mantovani A, Sozzani S, Locati M et al (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–555CrossRef

63.

Szulzewsky F, Arora S, de Witte L et al (2016) Human glioblastoma-associated microglia/monocytes express a distinct RNA profile compared to human control and murine samples. Glia 64:1416–1436. https://doi.org/10.1002/glia.23014CrossRefPubMed

64.

Gabrusiewicz K, Rodriguez B, Wei J et al (2016) Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. https://doi.org/10.1172/jci.insight.85841CrossRefPubMedPubMedCentral

65.

Zagzag D, Salnikow K, Chiriboga L et al (2005) Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Investig 85:328–341. https://doi.org/10.1038/labinvest.3700233CrossRefPubMed

66.

Romani M, Pistillo MP, Carosio R et al (2018) Immune checkpoints and innovative therapies in glioblastoma. Front Oncol 8:1–8. https://doi.org/10.3389/fonc.2018.00464CrossRef

67.

Christofides A, Kosmopoulos M, Piperi C (2014) Pathophysiological mechanisms regulated by cytokines in gliomas. Cytokine 71:377–384. https://doi.org/10.1016/j.cyto.2014.09.008CrossRefPubMed

68.

Iwami K, Natsume A, Wakabayashi T (2011) Cytokine networks in glioma. Neurosurg Rev 34:253–263. https://doi.org/10.1007/s10143-011-0320-yCrossRefPubMed

69.

Albulescu R, Codrici E, Popescu ID et al (2013) Cytokine patterns in brain tumour progression. Mediat Inflamm. https://doi.org/10.1155/2013/979748CrossRef

70.

Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967–975CrossRef

71.

Majmundar AJ, Wong WJ, Simon MC (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40:294–309CrossRef

72.

Shay JES, Celeste Simon M (2012) Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Semin Cell Dev Biol 23:389–394CrossRef

73.

Mangraviti A, Raghavan T, Volpin F et al (2017) HIF-1α- Targeting acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Sci Rep. https://doi.org/10.1038/s41598-017-14990-wCrossRefPubMedPubMedCentral

74.

Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104:2224–2234CrossRef

75.

Genard G, Lucas S, Michiels C (2017) Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front Immunol 8:828. https://doi.org/10.3389/fimmu.2017.00828CrossRefPubMedPubMedCentral

76.

Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86:1065–1073. https://doi.org/10.1189/jlb.0609385CrossRefPubMed

77.

Imtiyaz HZ, Williams EP, Hickey MM et al (2010) Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 120:2699–2714. https://doi.org/10.1172/JCI39506CrossRefPubMedPubMedCentral

78.

Talks KL, Turley H, Gatter KC et al (2000) The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411–421. https://doi.org/10.1016/S0002-9440(10)64554-3CrossRefPubMedPubMedCentral

79.

Galicich JH, French LA, Melby JC (1961) Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet 81:46–53PubMed

80.

Roth P, Wick W, Weller M (2010) Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol 23:597–602CrossRef

81.

Baschant U, Tuckermann J (2010) The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol 120:69–75. https://doi.org/10.1016/j.jsbmb.2010.03.058CrossRefPubMed

82.

Giles AJ, Hutchinson MKND, Sonnemann HM et al (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. https://doi.org/10.1186/s40425-018-0371-5CrossRefPubMedPubMedCentral

83.

Badie B, Schartner JM, Paul J et al (2000) Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 93:634–639. https://doi.org/10.3171/jns.2000.93.4.0634CrossRefPubMed

84.

Suryadevara CM, Desai R, Abel ML et al (2018) Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology. https://doi.org/10.1080/2162402X.2018.1434464CrossRefPubMedPubMedCentral

85.

Grossman SA, Ye X, Lesser G et al (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473–5480. https://doi.org/10.1158/1078-0432.CCR-11-0774CrossRefPubMedPubMedCentral

86.

Karachi A, Yang C, Dastmalchi F et al (2019) Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol 21:730–741. https://doi.org/10.1093/neuonc/noz015CrossRefPubMedPubMedCentral

Title: Immune suppression in gliomas
Authors: Matthew M. Grabowski
Eric W. Sankey
Katherine J. Ryan
Pakawat Chongsathidkiet
Selena J. Lorrey
Daniel S. Wilkinson
Peter E. Fecci
Publication date: 01-01-2021
Publisher: Springer US
Keywords: Glioblastoma
Glioma
Glioma
Glioblastoma
Glioblastoma
Glioma
Published in: Journal of Neuro-Oncology / Issue 1/2021
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03483-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immune suppression in gliomas

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Glucocorticoids and immune checkpoint inhibitors in glioblastoma

Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors

Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor

Publisher's Note

Journal of Neuro Oncology: immunotherapy for brain tumors

In situ vaccination with laser interstitial thermal therapy augments immunotherapy in malignant gliomas